|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US7498343||JANSSEN THERAP||Mycobacterial inhibitors|| |
(3 years from now)
|US8546428||JANSSEN THERAP||Fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol|| |
(5 years from now)
Sirturo is owned by Janssen Therap.
Sirturo contains Bedaquiline Fumarate.
Sirturo has a total of 2 drug patents out of which 0 drug patents have expired.
Sirturo was authorised for market use on 28 December, 2012.
Sirturo is available in tablet;oral dosage forms.
Sirturo can be used as treatment of pulmonary multi-drug resistant tuberculosis.
The generics of Sirturo are possible to be released after 19 March, 2029.
|Drug Exclusivity||Drug Exclusivity Expiration|
|Orphan Drug Exclusivity (ODE)||May 27, 2027|
Market Authorisation Date: 28 December, 2012
Treatment: Treatment of pulmonary multi-drug resistant tuberculosis
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic